J&J Pill Eases Psoriatic Arthritis Symptoms

A late-stage trial found once-daily icotrokinra improved joint symptoms more than placebo in adults with active psoriatic arthritis.

Updated on Nov. 7, 2026 in Arthritis

Photograph of a single white oval pill beside a softly blurred knee joint model in a bright clinical room, suggesting treatment for joint disease. — Johnson & Johnson reported that its once-daily pill icotrokinra improved joint symptoms more than placebo in adults with active psoriatic arthritis in a late-stage trial. AI Illustration. Upload story photo >

Live Poll

Would you trust a new once-daily pill to treat your joint pain?

Johnson & Johnson announced that its once-daily pill icotrokinra eased psoriatic arthritis symptoms in a late-stage trial. The drug also showed improvements in psoriasis skin symptoms in the same study.

Why it matters

Psoriatic arthritis is a long-term inflammatory condition that causes joint pain, swelling and stiffness, and about 30% of people with psoriasis also have it. Positive results could support expanded use of an oral option for patients.

In a 552-patient trial, 58% of icotrokinra patients achieved a 20% joint improvement after 16 weeks compared with 41% on placebo. Among patients with sufficient skin involvement, 57% had clear or nearly clear skin versus 14% on placebo, though longer-term durability was not reported.

The players

Johnson & Johnson

A multinational healthcare company headquartered in New Brunswick, New Jersey, that develops pharmaceuticals and medical devices.

The details

Johnson & Johnson's icotrokinra, branded as Icotyde, is a once-daily pill that was tested in adults with active psoriatic arthritis who had not previously received biologic medicines. The company reported that no new safety concerns were identified in the trial. Icotyde is already FDA-approved for moderate-to-severe plaque psoriasis.

16 weeks: duration of the trial measurement period for symptom and skin outcomes.
November 7, 2026: Johnson & Johnson announced the positive trial results.

Health Landscape

The results extend Icotyde's existing FDA approval for plaque psoriasis into psoriatic arthritis, a condition that often accompanies skin disease. Oral options have long been less common than injected biologics in this space, so a once-daily pill for patients new to biologics could shift treatment choices.

For adults with psoriatic arthritis, an oral once-daily option could offer an alternative to injected biologic medicines. The trial reported no new safety concerns, but patients should discuss any treatment change with their physician.

The takeaway

Psoriatic arthritis affects the joints as well as the skin, so patients with psoriasis should ask a doctor about joint symptoms. Oral treatment options may expand choices as new trial data emerges.